false 0001904286 0001904286 2023-12-01 2023-12-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 1, 2023

 

 

MIRA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Florida   001-41765   85-3354547
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

855 N Wolfe Street, Suite 601
Baltimore, Maryland 		  21205
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (737) 289-0835

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   MIRA   The Nasdaq Capital Market

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Director

 

On December 1, 2023, the Board of Directors of the Company unanimously approved the appointment of Mr. Michael Jerman as Chairman of the Audit Committee of the Board. Mr. Jerman had previously been appointed to serve on the Company’s Audit Committee on November 14, 2023.

 

Also, on December 1, 2023, Brian Daly resigned from the Board of Directors of the Company. At the time of Mr. Daly’s resignation, Mr. Daly served as the Chairperson of the Audit Committee, and a member of the Compensation Committee. Mr. Daly’s decision to resign did not involve disagreements with the Company, the Company’s management, or the Board of Directors on any matter relating to the Company’s operations, policies, or practices.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MIRA PHARMACEUTICALS, INC.
     
Date, December 1, 2023 By: /s/ Michelle Yanez
    Michelle Yanez
    Chief Financial Officer

 

 

 

v3.23.3
Cover
Dec. 01, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 01, 2023
Entity File Number 001-41765
Entity Registrant Name MIRA PHARMACEUTICALS, INC.
Entity Central Index Key 0001904286
Entity Tax Identification Number 85-3354547
Entity Incorporation, State or Country Code FL
Entity Address, Address Line One 855 N Wolfe Street
Entity Address, Address Line Two Suite 601
Entity Address, City or Town Baltimore
Entity Address, State or Province MD
Entity Address, Postal Zip Code 21205
City Area Code (737)
Local Phone Number 289-0835
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol MIRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
MIRA Pharmaceuticals (NASDAQ:MIRA)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more MIRA Pharmaceuticals Charts.
MIRA Pharmaceuticals (NASDAQ:MIRA)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more MIRA Pharmaceuticals Charts.